Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Morçӧl T, Hurst BL, Tarbet EB.

Vaccine. 2017 Aug 16;35(35 Pt B):4569-4577. doi: 10.1016/j.vaccine.2017.07.016. Epub 2017 Jul 14.

2.

Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice.

Morcol T, Nagappan P, Bell SJD, Cawthon AG.

AAPS PharmSciTech. 2019 Oct 7;20(8):315. doi: 10.1208/s12249-019-1530-9.

PMID:
31591662
3.

Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.

Wu CY, Chang CY, Ma HH, Wang CW, Chen YT, Hsiao PW, Chang CC, Chan CH, Liu CC, Chen JR.

Vaccine. 2014 Jul 31;32(35):4485-94. doi: 10.1016/j.vaccine.2014.06.043. Epub 2014 Jun 21.

4.

Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.

Proudfoot O, Esparon S, Tang CK, Laurie K, Barr I, Pietersz G.

BMC Infect Dis. 2015 Feb 26;15:101. doi: 10.1186/s12879-015-0838-7.

5.

Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.

Han HJ, Song MS, Park SJ, Byun HY, Robles NJC, Ha SH, Choi YK.

J Microbiol. 2019 Feb;57(2):163-169. doi: 10.1007/s12275-019-8504-1. Epub 2019 Jan 31.

PMID:
30706345
6.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
7.

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.

Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina MJ, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M.

Lancet Infect Dis. 2011 Feb;11(2):91-101. doi: 10.1016/S1473-3099(10)70296-6. Epub 2010 Dec 16.

PMID:
21168369
8.

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I.

Vaccine. 2010 Apr 19;28(18):3076-9. doi: 10.1016/j.vaccine.2010.02.050. Epub 2010 Mar 1.

PMID:
20193791
9.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

10.

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW.

Pediatr Infect Dis J. 2012 Aug;31(8):848-58. doi: 10.1097/INF.0b013e31825e6cd6.

PMID:
22801094
11.

A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.

Neuhaus V, Chichester JA, Ebensen T, Schwarz K, Hartman CE, Shoji Y, Guzmán CA, Yusibov V, Sewald K, Braun A.

Vaccine. 2014 May 30;32(26):3216-22. doi: 10.1016/j.vaccine.2014.04.011. Epub 2014 Apr 13.

12.

Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.

Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, Kawaoka Y.

Vaccine. 2012 Nov 6;30(48):6871-7. doi: 10.1016/j.vaccine.2012.09.007. Epub 2012 Sep 16.

13.

Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Vaccine. 2015 Jan 1;33(1):174-81. doi: 10.1016/j.vaccine.2014.10.085. Epub 2014 Nov 11.

PMID:
25444803
14.

Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.

Heath MD, Swan NJ, Marriott AC, Silman NJ, Hallis B, Prevosto C, Gooch KE, Skinner MA.

BMC Infect Dis. 2017 Mar 27;17(1):232. doi: 10.1186/s12879-017-2329-5.

16.

Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge.

Mallajosyula JK, Hiatt E, Hume S, Johnson A, Jeevan T, Chikwamba R, Pogue GP, Bratcher B, Haydon H, Webby RJ, McCormick AA.

Hum Vaccin Immunother. 2014;10(3):586-95. Epub 2013 Dec 30.

17.

Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.

Thomas M, Wang Z, Sreenivasan CC, Hause BM, Gourapura J Renukaradhya, Li F, Francis DH, Kaushik RS, Khatri M.

Vaccine. 2015 Jan 15;33(4):542-8. doi: 10.1016/j.vaccine.2014.11.034. Epub 2014 Nov 28.

PMID:
25437101
18.

Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.

Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T.

Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10.

PMID:
21911027
19.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.

Vaccine. 2012 May 14;30(23):3470-7. doi: 10.1016/j.vaccine.2012.03.017. Epub 2012 Mar 22.

PMID:
22446638
20.

Supplemental Content

Support Center